This article is more than 5 years old. Information may no longer be current.
HEAAL
Heart Failure Endpoint Evaluation with the Angiotensin II Antagonist Losartan
Click Here to Manage Email Alerts
Trial assessed use of high-dose losartan vs. low-dose losartan for the reduction of all-cause mortality or HF hospitalization.
Design: randomized, blinded
Patients: 3,834
Centers: 255
Countries: 30
RESULTS: The primary endpoint of all-cause mortality or HF hospitalization was reduced in patients receiving the high-dose losartan vs. the low-dose losartan with a median follow-up of 4.7 years (HR=0.90; 95% CI, 0.82-0.99). A total of 828 patients in the high-dose group and 889 in the low-dose group experienced the endpoint of death or HF hospitalization (P=.027). There were also reductions in the secondary endpoints of HF hospitalization (P=.025) and CV hospitalization (P=.023) in the high-dose losartan group. A trend toward reduced death or CV hospitalization was also reported in the high-dose group (P=.068). Adverse events occurring more often in the high-dose losartan group included renal impairment (P<.001), hypotension (P=.002) and hyperkalemia (P<.001), although the rates of discontinuations for these adverse events were small and not significantly different between groups.
Presented at AHA 2009.
Click here to read more about the HEAAL trial.